Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

ClinicalTrials.gov ID: NCT01061606

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01061606. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial is studying how well temsirolimus works in treating patients with recurrent or persistent cancer of the uterus. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study identification

NCT ID: NCT01061606
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 8 participants

Conditions and interventions

Conditions

Interventions

temsirolimus Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2010 (Type not available)
Primary completion: Apr 2012 (Actual)
Completion: Oct 2012 (Actual)
Last update posted: Nov 9, 2016

2010 – 2012

United States locations

U.S. sites: 20
U.S. states: 6
U.S. cities: 14

Facility	City	State	ZIP	Site status
Tower Cancer Research Foundation	Beverly Hills	California	90211-1850	—
City of Hope	Duarte	California	91010	—
Los Angeles County-USC Medical Center	Los Angeles	California	90033	—
City of Hope Medical Group Inc	Pasadena	California	91105	—
University of California at Davis Cancer Center	Sacramento	California	95817	—
University of Connecticut	Farmington	Connecticut	06030	—
Yale University	New Haven	Connecticut	06520	—
Morristown Memorial Hospital	Morristown	New Jersey	07962	—
The Valley Hospital-Luckow Pavilion	Paramus	New Jersey	07652	—
Women's Cancer Care Associates LLC	Albany	New York	12208	—
Beth Israel Medical Center	New York	New York	10003	—
New York University Langone Medical Center	New York	New York	10016	—
Saint Luke's Roosevelt Hospital Center - Roosevelt Division	New York	New York	10019	—
Presbyterian-Weill Medical College	New York	New York	10021	—
Mount Sinai School of Medicine	New York	New York	10029	—
Children's Hospital of New York Presbyterian	New York	New York	10032	—
Columbia University College of Physicians and Surgeons	New York	New York	10032	—
Montefiore Medical Center - Moses Campus	The Bronx	New York	10467-2490	—
Penn State Hershey Children's Hospital	Hershey	Pennsylvania	17033	—
University of Texas Health Science Center at San Antonio	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01061606, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 9, 2016 · Synced Nov 13, 2026